CT-P55

BIOLOGICAL3 trials

Sponsors

Celltrion Inc., Celltrion

Conditions

Healthy Male SubjectsPlaque PsoriasisPlaque psoriasis

Phase 1

To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects

CompletedNCT07054970

CelltrionHealthy Male Subjects

Start: 2024-01-12End: 2024-09-06Updated: 2025-07-08

Phase 3

A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis

Active, not recruitingNCT06630559

CelltrionPlaque Psoriasis

Start: 2025-05-26End: 2026-10-01Updated: 2026-02-23

A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderate to Severe Plaque Psoriasis

Active, not recruitingCTIS2024-513348-27-00

Celltrion Inc.Plaque psoriasis

Start: 2025-05-09Target: 375Updated: 2025-07-01

Related Papers

Pharmacokinetics and safety of candidate biosimilar CTP55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, phase I study.

2026-02-10